APPLICATION OF "L-BIOCOMPLEX" IN CHRONIC HEART FAILURE TREATMENT IN PATIENTS WITH METABOLIC SYNDROME

Abstract

The combination of chronic heart failure and metabolic syndrome is a common clinical case. Patients with this pathology belong to the group of a high cardiovascular risk, which is explained by the higher frequency and severity of traditional cardiovascular factors. Of particular interest is the use of "L−BIOCOMPLEX (liposomal)" dietary supplement of "Biolik" company (Kharkiv, Ukraine), available in liposomal form as a set of L−carnitine + thioctic acid in cardiovascular pathology. To study its effect on treatment efficiency, 40 patients with chronic heart failure in combination with metabolic syndrome were examined. The treatment result for the patients whose complex treatment included "L−BIOCOMPLEX" at a dose of 5 ml of L−carnitine and 10 ml of thioctic acid once a day 30 minutes before meals for four weeks, and those receiving only basic therapy. It has been shown that L−BIOCOMPLEX as an additive to standard therapy improves the clinical and functional state of patients: reduces the functional class of chronic heart failure, increases exercise tolerance, enhances diastolic heart function and boosts the left ventricular ejection fraction in the left ventricle. The inclusion of "L−BIOCOMPLEX" in the traditional scheme of therapy helped to improve the quality of life of patients. As part of the combination therapy of the patients with chronic heart failure the "L−BIOCOMPLEX" positively affects lipid and carbohydrate metabolism, reduces atherogenic lipids, diminishes the severity of insulin resistance. Thus, "L−BIOCOMPLEX" has a positive influence on additional risk factors, affecting the cardiovascular prognosis and playing a significant role in the mechanisms of development and progression of heart failure. Key words: "L−BIOCOMPLEX", L−carnitine, thioctic acid, chronic heart failure, metabolic syndrome.